DeLLphi-312
Phase 3 Recruiting
330 enrolled
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Phase 2/3 Recruiting
596 enrolled
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
Phase 3 Recruiting
420 enrolled
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Phase 2/3 Recruiting
1,260 enrolled
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
660 enrolled
CheckMate-1533
Phase 2 Recruiting
76 enrolled
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Phase 2/3 Recruiting
854 enrolled
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Phase 2/3 Recruiting
470 enrolled
A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer
Phase 3 Recruiting
720 enrolled
LuCa-MERIT-1
Phase 1 Recruiting
320 enrolled
A Study of ASP3082 in Adults With Advanced Solid Tumors
Phase 1 Recruiting
681 enrolled
INTerpath-009
Phase 3 Recruiting
680 enrolled
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Phase 2 Recruiting
140 enrolled
SEZanne
Phase 2 Recruiting
180 enrolled
DL03
Phase 1 Recruiting
304 enrolled
PALOMA-2
Phase 2 Recruiting
520 enrolled
MRD
Phase 1/2 Recruiting
30 enrolled
TroFuse-019
Phase 3 Recruiting
780 enrolled
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
Phase 1 Recruiting
500 enrolled
OrigAMI-4
Phase 1/2 Recruiting
287 enrolled
eVOLVE-01
Phase 2 Recruiting
180 enrolled
SUPRAME
Phase 3 Recruiting
360 enrolled
Krascendo 2
Phase 3 Recruiting
600 enrolled
TroFuse-011
Phase 3 Recruiting
1,000 enrolled
OVATION-3
Phase 3 Recruiting
500 enrolled
TroFuse-033
Phase 3 Recruiting
1,123 enrolled
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Phase 3 Recruiting
2,400 enrolled
KANDLELIT-007
Phase 3 Recruiting
675 enrolled
INTerpath-13
Phase 2 Recruiting
180 enrolled
MK-6070-003
Phase 1/2 Recruiting
170 enrolled
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Phase 2 Recruiting
130 enrolled
OrigAMI-5
Phase 3 Recruiting
500 enrolled
TroFuse-036
Phase 3 Recruiting
1,023 enrolled
OLYMPIA-4
Phase 3 Recruiting
216 enrolled
DE-01
Phase 3 Recruiting
600 enrolled
A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer
Phase 2 Recruiting
200 enrolled
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
Phase 3 Recruiting
1,800 enrolled
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Phase 1 Recruiting
1,006 enrolled
MUIR
Phase 1 Recruiting
172 enrolled
RAINFOL-01
Phase 1/2 Recruiting
764 enrolled
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Phase 3 Recruiting
630 enrolled
MountainTAP-29
Phase 2/3 Recruiting
590 enrolled
REZILIENT4
Phase 3 Recruiting
360 enrolled
TRANSPARENT
Phase 4 Recruiting
100 enrolled
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Phase 2 Recruiting
377 enrolled
iMATRIX GLO
Phase 1/2 Recruiting
65 enrolled
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
Phase 1 Recruiting
339 enrolled
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Phase 3 Recruiting
530 enrolled
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Phase 1/2 Recruiting
295 enrolled
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Phase 1/2 Recruiting
434 enrolled